Kim Hanah, Hur Mina, Lee Seungho, Marino Rossella, Magrini Laura, Cardelli Patrizia, Struck Joachim, Bergmann Andreas, Hartmann Oliver, Di Somma Salvatore
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
School of Public Health, Seoul National University, Seoul, Korea.
Ann Lab Med. 2017 Sep;37(5):388-397. doi: 10.3343/alm.2017.37.5.388.
Proenkephalin (PENK) has been suggested as a novel biomarker for kidney function. We investigated the diagnostic and prognostic utility of plasma PENK in comparison with neutrophil gelatinase-associated lipocalin (NGAL) and estimated glomerular filtration rates (eGFR) in septic patients.
A total of 167 septic patients were enrolled: 99 with sepsis, 37 with septic shock, and 31 with suspected sepsis. PENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC). The PENK, NGAL, and eGFR results were compared according to sepsis severity, presence or absence of acute kidney injury (AKI), and clinical outcomes.
The PENK, NGAL, and eGFR results were significantly associated with sepsis severity and differed significantly between patients with and without AKI only in the sepsis group (all P<0.05). PENK was superior to NGAL in predicting AKI (P=0.022) and renal replacement therapy (RRT) (P=0.0085). Regardless of the variable GFR category by the different eGFR equations, PENK showed constant and significant associations with all eGFR equations. Unlike NGAL, PENK was not influenced by inflammation and predicted the 30-day mortality.
PENK is a highly sensitive and objective biomarker of AKI and RRT and is useful for prognosis prediction in septic patients. With its diagnostic robustness and predictive power for survival, PENK constitutes a promising biomarker in critical care settings including sepsis.
前脑啡肽原(PENK)已被认为是一种用于评估肾功能的新型生物标志物。我们研究了脓毒症患者血浆PENK相对于中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和估计肾小球滤过率(eGFR)的诊断及预后价值。
共纳入167例脓毒症患者,其中99例为脓毒症,37例为脓毒性休克,31例为疑似脓毒症。检测PENK和NGAL浓度,并使用同位素稀释质谱法可溯源的肾脏病饮食改良(MDRD)研究公式以及三个慢性肾脏病流行病学协作组(CKD-EPI)公式:CKD-EPI(Cr)、CKD-EPI(CysC)和CKD-EPI(Cr-CysC)来估计肾小球滤过率。根据脓毒症严重程度、是否存在急性肾损伤(AKI)以及临床结局,比较PENK、NGAL和eGFR的结果。
PENK、NGAL和eGFR结果与脓毒症严重程度显著相关,且仅在脓毒症组中,有或无AKI的患者之间存在显著差异(所有P<0.05)。在预测AKI(P=0.022)和肾脏替代治疗(RRT)(P=0.0085)方面,PENK优于NGAL。无论不同eGFR公式得出的GFR类别如何,PENK与所有eGFR公式均呈现持续且显著的相关性。与NGAL不同,PENK不受炎症影响,并能预测30天死亡率。
PENK是AKI和RRT的高度敏感且客观的生物标志物,对脓毒症患者的预后预测有用。鉴于其诊断稳健性和生存预测能力,PENK在包括脓毒症在内的重症监护环境中是一种有前景的生物标志物。